SYNACT PHARMA
SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis. Preclinical studies show that AP1189 has a unique ability to both reduce inflammation and accelerate bleeding, which is expected to reduce joint damage that may occur after acute inflammation of the ... joints of the joints. AP1189 has the potential to be given in tablet form once a day. Results from a clinical phase I study are expected to be available during Q2 2018. The company intends to prepare for a first patient study in parallel with the completion of the phase I study. Assuming that AP1189 has proven safe and tolerable also in multiple dosing, the aim is to submit a clinical trial application (CTA) in patients with active arthritis (joint inflammation). After proof of concept has been shown in patients, the company intends to sign commercial agreements with one or more major pharmaceutical companies.
SYNACT PHARMA
Industry:
Biotechnology Health Care
Founded:
2012-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.synactpharma.com
Total Employee:
1+
Status:
Active
Contact:
+45 28 44 75 67
Email Addresses:
[email protected]
Total Funding:
71.43 K EUR
Technology used in webpage:
SSL By Default Content Delivery Network Global Site Tag Cloudflare JS CDN JS COVID-19 DoubleClick.Net Google Analytics 4 Twemoji Vimeo
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - SynAct Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-07 | SynAct Pharma appoints Patrik Renblad as CFO |
| 2021-01-26 | SynAct Pharma names Thomas Boesen as Chief Operating Officer |
Official Site Inspections
http://www.synactpharma.com Semrush global rank: 4.85 M Semrush visits lastest month: 1.84 K
- Host name: 104.18.12.243
- IP address: 104.18.12.243
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
